Sandoz Patent Challenge On Amgen’s Enbrel Must Follow Biosimilar Application
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite Federal Circuit ruling, biosimilar sponsors might still be able to avoid pathway’s convoluted patent dispute resolution process by filing declaratory judgment action.